FIGARO-DKD and FIDELITY Analysis: Key Takeaways

FIGARO-DKD and FIDELITY Analysis: Key Takeaways

FIGARO-DKD and FIDELITY Analysis: Key Takeaways

Experts discuss “Hot Line” data presented at the ESC Congress 2021 on using MRAs to improve CV and renal outcomes in patients with diabetes and CKD.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Rajiv Agarwal, MBBS, MD, FASN, BRCU
    Professor of Medicine
    Indiana University School of Medicine
    Indianapolis, IN

    Consulting Fees: Akebia, Bayer, Boehringer, Diamedica, Janssen, Merck, Reata, Relypsa, Sanofi
    Other: Data safety board: AstraZeneca, Chinook

    George L. Bakris, MD
    Professor of Medicine
    Director, Am Heart Assoc. Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, IL

    Consulting Fees: Alnylam, Ionis, Merck, Relypsa

    Bertram Pitt, MD
    Professor of Medicine, Emeritus
    University of Michigan School of Medicine
    Ann Arbor, MI

    Consulting Fees/Honoraria: Bayer, Tricida, AstraZeneca, Boehringer Ingelheim Pharmaceutical, Inc, Merck & Co., Inc., scPharmaceuticals, KBP Biosciences, Johnson & Johnson, Novartis, Relypsa, Inc, a Vifor Pharma Group Company.
    Ownership/Partnership/Principal: scPharmaceuticals, Tricida, KBP Biosciences

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the potential clinical impact of the latest clinical trial data presented at the ESC Congress 2021
    • Develop treatment strategies for the care of patients with CKD in T2D utilizing the latest clinical data results
    • Evaluate treatment strategies for CKD in T2D to optimize cardiorenal outcomes
    • Assess the most recent efficacy and safety data for MRAs in the treatment of CKD in T2D
    • Select appropriate therapies based on the individual needs of patients with CKD in T2D
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, endocrinologists, cardiologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free